A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HR+/HER2-negative Breast Cancer|Metastasis
Interventions: DRUG: Fulvestrant + palbociclib
Sponsor: Assistance Publique - Hôpitaux de Paris